Drug-induced acute liver failure and gastrointestinal complications

Critical Care Medicine

Volumn 38, Issue 6 SUPPL., 2010, Pages

  Lat, Ishaq ^a   Foster, David R ^b,c   Erstad, Brian ^d  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Department of Medicine ^*  (United States)

^d UNIVERSITY OF ARIZONA   (United States)

Author keywords

Adverse drug events; Constipation; Critical illness; Diarrhea; Gastrointestinal bleeding; Intensive care; Liver failure; Motility; Pancreatitis

Indexed keywords

AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CHLOROQUINE; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; DESFLURANE; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; HALOTHANE; ISOFLURANE; ISONIAZID; KETOCONAZOLE; LAMOTRIGINE; METHOTREXATE; NITROFURANTOIN; OXCARBAZEPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; RIFAMPICIN; TAMOXIFEN; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ACUTE PANCREATITIS; AMINOTRANSFERASE BLOOD LEVEL; ARTHRALGIA; BLOOD CLOTTING DISORDER; CHOLESTASIS; CONSTIPATION; CRITICALLY ILL PATIENT; DIARRHEA; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRESS SYNDROME; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG WITHDRAWAL; EOSINOPHILIA; FATIGUE; FATTY LIVER; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TOXICITY; HEPATIC ENCEPHALOPATHY; HUMAN; INTENSIVE CARE UNIT; INTESTINAL DYSMOTILITY; JAUNDICE; LIVER CELL DAMAGE; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; MANAGED CARE; MORBIDITY; MORTALITY; MULTIPLE ORGAN FAILURE; NAUSEA; NONALCOHOLIC FATTY LIVER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; VOMITING;

EID: 77953040194     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0b013e3181de0db2     Document Type: Article

References (162)

1. Lee WM: Etiologies of acute liver failure. Semin Liver Dis 2008; 28:142-152
2. Navarro VJ, Senior JR: Drug-related hepatotoxicity. N Engl J Med 2006; 354:731-739
3. Ostapowicz G, Fontana RJ, Schiodt FV, et al: Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137: 947-954
4. Larson AM, Polson J, Fontana RJ, et al: Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 2005; 42: 1364-1372
5. Pessayre O, Larrey D, Biour M: Druginduced liver injury. Oxford textbook of clinical hepatology. Second Edition. Oxford, UK, Oxford University Press, 1999, pp 1261-1315
6. Zimmerman HJ: The adverse effects of drugs and other chemicals on the liver. Second Edition. Philadelphia, PA, Lippincott Williams & Wilkins, 1999
7. Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002; 22: 145-155
8. Sgro C, Clinard F, Ouazir K, et al: Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002; 36:451-455
9. Kim JW, Phongsamran PV: Drug-induced liver disease and drug use considerations in liver disease. J Pharm Pract 2009; 22: 278-289
10. Lee WM: Acute liver failure in the United States. Semin Liver Dis 2003; 23:217-226
11. Hoofnagle JH, Carithers RL, Shapiro C, et al: Fulminant hepatic failure: Summary of a workshop. Hepatology 1995; 21:240-252
12. Mindikoglu AL, Magder LS, Regev A: Outcome of liver transplantation of druginduced acute liver failure in the United States: Analysis of the united network for organ sharing database. Liver Transpl 2009; 15:719-729
13. Williams R: Fulminant hepatic failure. Semin Liver Dis 2003; 23:201-202
14. Williams R: Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis 1996; 16:343-348
15. Polson J, Lee WM: AASLD Position Paper: The management of acute liver failure. Hepatology 2005; 41:1179-1197
16. Larrey D, Pageaux GP: Drug-induced acute liver failure. Eur J Gastroenterol Hepatol 2005; 17:141-143
17. Trotter JF: Practical management of acute liver failure in the intensive care unit. Curr Opin Crit Care 2009; 15:163-167
18. Stravitz RT: Critical management decisions in patients with acute liver failure. Chest 2008; 134:1092-1102
19. Kaplowitz N: Drug-induced liver injury. Clin Infect Dis 2008; 38(Suppl 2):S44-S48
20. Lee WM: Drug-induced hepatotoxicity. N Engl J Med 2003; 349:474-485
21. Maria VA, Victorino RM: Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26:664-669
22. Aithal GP, Rawlins MD, Day CP: Clinical diagnostic scale: A useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J Hepatol 2000; 33:949-952
23. Lucena MO, Camargo R, Andrade RJ, et al: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001; 33:123-130
24. Beune PH, Lecoeur J: Immunotoxicity of the liver: Adverse reactions to drugs. J Hepatol 1997; 26(Suppl 2):37-42
25. Robin MA, Le Roy M, Descatoire V, et al: Plasma membrane cytochrome P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 1997; 26(Suppl 2):23-30
26. Smythe MA, Umstead GS: Phenytoin hepatotoxicity: A review of the literature. DICP 1989; 23:13-18
27. Kleckner H, Yajulis V, Heller P: Severe hypersensitivity to diphenylhydantoin with circulating anitbodies to the drug. Ann Intern Med 1975; 83:522-523
28. Alvestad S, Lydersen S, Brodtkorb E: Crossreactivity pattern of rash from current antiepileptic drugs. Epilepsy Res 2008; 80: 194-200
29. Kaufman KR: Carbamazepine, hepatotoxicity, organic solvents, and paints. Seizure 1999; 8:250-252
30. Sussman NM, McLain W: A direct hepatotoxic effect of valproic acid. JAMA 1979; 242:1173-1174
31. Chang TH, Abbott FS: Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev 2006; 38: 255-268
32. Gilinsky NH, Briscoe GW, Kuo CS: Fatal amiodarone hepatotoxicity. Am J Gastroenterol 1988; 83:161-163
33. Rigas B, Rosenfeld LE, Barwick KW, et al: Amiodarone hepatotoxicity. A clinicopathological study of five patients. Ann Intern Med 1986; 104:348-351
34. Rigas B: The evolving spectrum of amiodarone hepatoxicity. Hepatology 2005; 10: 116-117
35. Kharasch ED, Hankins DC, Fenstamaker K, et al: Human halothane metabolism, lipid peroxidation, and cytochromes P(450)2A6 and P(450)3A4. Eur J Clin Pharmacol 2000; 55:853-859
36. Stachnik J: Inhaled anesthetic agents. Am J Health Syst Pharm 2006; 63:623-634
37. Bjornsson E, Olsson R: Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481-489
38. Fontana RJ, Shakil AO, Greenson JK, et al: Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci 2005; 10:1785-1790
39. Fontana RJ: Acute liver failure due to drugs. Semin Dig Dis 2008; 28:175-187
40. Fountain FF, Tolley E, Chrisman CR, et al: Isonizaid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128:116-123
41. Fountain FF, Tolley E, Jacobs A, et al: Rifampin hepatotoxicity associated with treatment of latent tuberculosis infeciton. Am J Med Sci 2009; 337:317-320
42. Fischer MA, Winkelmayer WC, Rubin RH, et al: The hepatotoxicity of antifungal medications in bone marrow transplant recipients. Clin Infect Dis 2005; 41:308-310
43. Denning DW, Lee JY, Hostetler JS, et al: NIAID mycoses study group multicenter trial of oral itraconazole for invasive aspergillosis. Am J Med 1994; 97:135-144
44. Buchi KN, Gray PD, Tolman KG: Ketoconazole hepatotoxicity: An in vitro model. Biochem Pharmacol 1986; 35:2845-2847
45. DeSanty KP, Amabile CM: Antidepressantinduced liver injury. Ann Pharmacother 2007; 41:1201-1211
46. Hayes BD, Klein-Schwartz W, Doyon S: Frequency of emdication errors with intravenous acetylcysteine for acetaminophen overdose. Ann Pharmacother 2008; 42: 766-770
47. Lee WM, Hynan LS, Rossaro L, et al: Intravenous N-acetylcysteine improves transplant-free survival in early stage nonacetaminophen acute liver failure. Gastroenterology 2009; 137:856-864
48. Dechene A, Treicherl U, Gerken G, et al: Effectiveness of a steroid and ursodeoxycholic acid combination therapy with druginduced subacute liver failure. Hepatology 2005; 42:A358
49. Rakela J, Mosley JW, Edwards VM, et al: A double-blinded randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 1991; 36:1223-1228
50. Randomized trial of steroid therapy in acute liver failure. Report from the European Association for the Study of the Liver (EASL). Gut 1979; 20:620-623
51. Annane D, Sebille V, Charpentier C, et al: Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288:862-871
52. Sprung CL, Annane D, Keh D, et al: Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124
53. Ritz MA, Fraser R, Edwards N, et al: Delayed gastric emptying in ventilated critically ill patients: Measurement by 13 C-octanoic acid breath test. Crit Care Med 2001; 29: 1744-1749
54. Fruhwald S, Holzer P, Metzler H: Intestinal motility disturbances in intensive care patients pathogenesis and clinical impact. Intensive Care Med 2007; 33:36-44
55. Rohm KD, Boldt J, Piper SN: Motility disorders in the ICU: Recent therapeutic options and clinical practice. Curr Opin Clin Nutr Metab Care 2009; 12:161-167
56. Fruhwald S, Holzer P, Metzler H: Gastrointestinal motility in acute illness. Wien Klin Wochenschr 2008; 120:6-17
57. Quigley EM: Critical care dysmotility: Abnormal foregut motor function in the ICU/ ITU patient. Gut 2005; 54:1351-1352
58. Dive A, Foret F, Jamart J, et al: Effect of dopamine on gastrointestinal motility during critical illness. Intensive Care Med 2000; 26:901-907
59. Fruhwald S, Scheidl S, Toller W, et al: Low potential of dobutamine and dopexamine to block intestinal peristalsis as compared with other catecholamines. Crit Care Med 2000; 28:2893-2897
60. Bosscha K, Nieuwenhuijs VB, Vos A, et al: Gastrointestinal motility and gastric tube feeding in mechanically ventilated patients. Crit Care Med 1998; 26:1510-1517
61. Clemens KE, Klaschik E: Management of constipation in palliative care patients. Curr Opin Support Palliat Care 2008; 2:22-27
62. Mostafa SM, Bhandari S, Ritchie G, et al: Constipation and its implications in the critically ill patient. Br J Anaesth 2003; 91: 815-819
63. Patanwala AE, Abarca J, Huckleberry Y, et al: Pharmacologic management of constipation in the critically ill patient. Pharmacotherapy 2006; 26:896-902
64. Gervasio JM. Diarrhea and Constipation. In: Drug-induced diseases; prevention, detection, and management. First Edition. Tisdale JE, Miller DA (Eds). Bethesda, MD, American Society of Health System Pharmacists, 2005, pp 501-514
65. Thomas JR, Cooney GA, Slatkin NE: Palliative care and pain: New strategies for managing opioid bowel dysfunction. J Palliat Med 2008; 11(Suppl 1):S1-S19
66. Ratnaike RN, Milton AG, Nigro O: Drugassociated diarrhoea and constipation in older people. Aust J Hosp Pharm 2000; 30: 210-213
67. Kolbel CB, Rippel K, Klar H, et al: Esophageal motility disorders in critically ill patients: A 24-hour manometric study. Intensive Care Med 2000; 26:1421-1427
68. Mentec H, Dupont H, Bocchetti M, et al: Upper digestive intolerance during enteral nutrition in critically ill patients: Frequency, risk factors, and complications. Crit Care Med 2001; 29:1955-1961
69. James AN, Ryan JP, Parkman HP: Effects of clonidine and tricyclic antidepressants on gastric smooth muscle contractility. Neurogastroenterol Motil 2004; 16:143-153
70. Stieger DS, Cantieni R, Frutiger A: Acute colonic pseudoobstruction (Ogilvie's syndrome) in two patients receiving high dose clonidine for delirium tremens. Intensive Care Med 1997; 23:780-782
71. Nguyen NQ, Chapman MJ, Fraser RJ, et al: The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med 2008; 34: 454-460
72. Panchal SJ, Muller-Schwefe P, Wurzelmann JI: Opioid-induced bowel dysfunction: Prevalence, pathophysiology and burden. Int J Clin Pract 2007; 61:1181-1187
73. Kraft MD: Emerging pharmacologic options for treating postoperative ileus. Am J Health Syst Pharm 2007; 64:S13-S20
74. MacLaren R, Kiser TH, Fish DN, et al: Erythromycin vs metoclopramide for facilitating gastric emptying and tolerance to intragastric nutrition in critically ill patients. JPEN J Parenter Enteral Nutr 2008; 32:412-419
75. Landzinski J, Kiser TH, Fish DN, et al: Gastric motility function in critically ill patients tolerant vs intolerant to gastric nutrition. JPEN J Parenter Enteral Nutr 2008; 32:45-50
76. Booth CM, Heyland DK, Paterson WG: Gastrointestinal promotility drugs in the critical care setting: A systematic review of the evidence. Crit Care Med 2002; 30: 1429-1435
77. Hawkyard CV, Koerner RJ: The use of erythromycin as a gastrointestinal prokinetic agent in adult critical care: Benefits versus risks. J Antimicrob Chemother 2007; 59: 347-358
78. Nguyen NQ, Chapman MJ, Fraser RJ, et al: Erythromycin is more effective than metoclopramide in the treatment of feed intolerance in critical illness. Crit Care Med 2007; 35:483-489
79. Dorman BP, Hill C, McGarth M, et al: Bowel management in the intensive care unit. Intensive Crit Care Nurs 2004; 20:320-329
80. Hawley PH, Byeon JJ: A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. J Palliat Med 2008; 11:575-581
81. Hurdon V, Viola R, Schroder C: How useful is docusate in patients at risk for constipation? A systematic review of the evidence in the chronically ill. J Pain Symptom Manage 2000; 19:130-136
82. DiPalma JA, Cleveland MB, McGowan J, et al: A comparison of polyethylene glycol laxative and placebo for relief of constipation from constipating medications. South Med J 2007; 100:1085-1090 (Pubitemid 350071173)
83. Zingg U, Miskovic D, Pasternak I, et al: Effect of bisacodyl on postoperative bowel motility in elective colorectal surgery: A prospective, randomized trial. Int J Colorectal Dis 2008; 23:1175-1183
84. Herbert MK, Holzer P: Standardized concept for the treatment of gastrointestinal dysmotility in critically ill patients-Current status and future options. Clin Nutr 2008; 27:25-41
85. Becker G, Blum HE: Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus. Lancet 2009; 373: 1198-1206
86. Traut U, Brugger L, Kunz R, et al: Systemic prokinetic pharmacologic treatment for postoperative adynamic ileus following abdominal surgery in adults. Cochrane Database Syst Rev 2008; CD004930
87. Meissner W, Dohrn B, Reinhart K: Enteral naloxone reduces gastric tube reflux and frequency of pneumonia in critical care patients during opioid analgesia. Crit Care Med 2003; 31:776-780
88. Thomas J, Karver S, Cooney GA, et al: Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 2008; 358:2332-2343
89. Relistor (methylnaltrexone bromide) subcutaneous injection. Full prescribing information. Philadelphia, PA, Wyeth Pharmaceuticals, 2009
90. Entereg (alvimopan) capsules. Full prescribing information. Research Triangle Park, NC, GlaxoSmithKline, 2008
91. Gannon RH: Current strategies for preventing or ameliorating postoperative ileus: A multimodal approach. Am J Health Syst Pharm 2007; 64:8-12
92. Chassany O, Michaux A, Bergmann JF: Drug-induced diarrhoea. Drug Saf 2000; 22: 53-72
93. Wiesen P, Van GA, Preiser JC: Diarrhoea in the critically ill. Curr Opin Crit Care 2006; 12:149-154
94. Abraham B, Sellin JH: Drug-induced diarrhea. Curr Gastroenterol Rep 2007; 9:365-372
95. Sabol VK, Carlson KK. Diarrhea: Applying research to bedside practice. AACN Adv Crit Care 2007; 18:32-44
96. Caines C, Gill MV, Cunha BA: NonClostridium difficile nosocomial diarrhea in the intensive care unit. Heart Lung 1997; 26:83-84
97. Marcon AP, Gamba MA, Vianna LA: Nosocomial diarrhea in the intensive care unit. Braz J Infect Dis 2006; 10:384-389
98. Davies NM: Toxicity of nonsteroidal antiinflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38:1311-1321
99. Dial S, Alrasadi K, Manoukian C, et al: Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: Cohort and case-control studies. CMAJ 2004; 171:33-38
100. Cunningham R, Dale B, Undy B, et al: Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54:243-245
101. Meier RF: Probiotics: A new treatment for antibiotic-associated diarrhea? Digestion 2005; 72:49-50
102. Can M, Besirbellioglu BA, Avci IY, et al: Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Med Sci Monit 2006; 12:I19-I22
103. Watkinson PJ, Barber VS, Dark P, et al: The use of preproand synbiotics in adult intensive care unit patients: Systematic review. Clin Nutr 2007; 26:182-192
104. Elia M, Engfer MB, Green CJ, et al: Systematic review and meta-analysis: The clinical and physiological effects of fibre-containing enteral formulae. Aliment Pharmacol Ther 2008; 27:120-145
105. Madsen K: Probiotics in critically ill patients. J Clin Gastroenterol 2008; 42(Suppl 3 Pt 1):S116-S118
106. American Society of Health-Systems Pharmacists therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm 1999; 56:347-379
107. Spirt MJ: Stress-related mucosal disease: Risk factors and prophylactic therapy. Clin Ther 2004; 26:197-213
108. Choung RS, Talley NJ: Epidemiology and clinical presentation of stress-related peptic damage and chronic peptic ulcer. Curr Mol Med 2008; 8:253-257
109. Fennerty MB: Pathophysiology of the upper gastrointestinal tract in the critically ill patient: Rationale for the therapeutic benefits of acid suppression. Crit Care Med 2002; 30:S351-S355
110. Mutlu GM, Mutlu EA, Factor P: GI complications in patients receiving mechanical ventilation. Chest 2001; 119:1222-1241
111. Ben-Menachem T, Fogel R, Patel RV, et al: Prophylaxis for stress-related gastric hemorrhage in the medical intensive care unit. A randomized, controlled, single-blind study. Ann Intern Med 1994; 121:568-575
112. Cook DJ, Fuller HD, Guyatt GH, et al: Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330: 377-381
113. Bandyopadhyay U, Biswas K, Bandyopadhyay D, et al: Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase-Two important gastroprotective enzymes. Mol Cell Biochem 1999; 202: 31-36
114. Brush BE, Block MA, Geoghegan T, et al: The steroid-induced peptic ulcer. AMA Arch Surg 1957; 74:675-679
115. Carpani de KM, Rentsch R, Levi S, et al: Corticosteroids reduce regenerative repair of epithelium in experimental gastric ulcers. Gut 1995; 37:613-616
116. Luo JC, Shin VY, Liu ES, et al: Nonulcerogenic dose of dexamethasone delays gastric ulcer healing in rats. J Pharmacol Exp Ther 2003; 307:692-698
117. Beyth RJ: Hemorrhagic complications of oral anticoagulant therapy. Clin Geriatr Med 2001; 17:49-56
118. Qadeer MA, Richter JE, Brotman DJ: Hospital-acquired gastrointestinal bleeding outside the critical care unit: Risk factors, role of acid suppression, and endoscopy findings. J Hosp Med 2006; 1:13-20
119. Terdiman JP, Ostroff JW: Gastrointestinal bleeding in the hospitalized patient: A casecontrol study to assess risk factors, causes, and outcome. Am J Med 1998; 104:349-354
120. Siepler JK, Maas C. In: Drug-induced diseases; prevention, detection, and management. First Edition. Tisdale JE, Miller DA (Eds). Bethesda, MD, American Society of Health System Pharmacists, 2005, pp 489-500
121. Estruch R, Pedrol E, Castells A, et al: Prophylaxis of gastrointestinal tract bleeding with magaldrate in patients admitted to a general hospital ward. Scand J Gastroenterol 1991; 26:819-826
122. Annane D, Bellissant E, Bollaert PE, et al: Corticosteroids in the treatment of severe sepsis and septic shock in adults: A systematic review. JAMA 2009; 301:2362-2375
123. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
124. Fumagalli R, Mignini MA: The safety profile of drotrecogin alfa (activated). Crit Care 2007; 11(Suppl 5):S6
125. Cook DJ, Pearl RG, Cook RJ, et al: Incidence of clinically important bleeding in mechanically ventilated patients. J Intensive Care Med 1991; 6:167-174
126. Conrad SA, Gabrielli A, Margolis B, et al: Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. Crit Care Med 2005; 33:760-765
127. Cook D, Guyatt G, Marshall J, et al: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 1998; 338:791-797
128. Bhatt DL, Scheiman J, Abraham NS, et al: ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2008; 118:1894-1909
129. Lanza FL, Chan FK, Quigley EM: Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104: 728-738
130. Conrad SA: Acute upper gastrointestinal bleeding in critically ill patients: Causes and treatment modalities. Crit Care Med 2002; 30:S365-S368
131. Gralnek IM, Barkun AN, Bardou M: Management of acute bleeding from a peptic ulcer. N Engl J Med 2008; 359:928-937
132. Tonsi AF, Bacchion M, Crippa S, et al: Acute pancreatitis at the beginning of the 21st century: the state of the art. World J Gastroenterol 2009; 15:2945-2959
133. Wilmink T, Frick TW: Drug-induced pancreatitis. Drug Saf 1996; 14:406-423
134. Kaurich T: Drug-induced acute pancreatitis. Proc (Bayl Univ Med Cent) 2008; 21: 77-81
135. Underwood TW, Frye CB: Drug-induced pancreatitis. Clin Pharm 1993; 12:440-448
136. Banerjee AK, Patel KJ, Grainger SL: Druginduced acute pancreatitis. A critical review. Med Toxicol Adverse Drug Exp 1989; 4:186-198
137. Badalov N, Baradarian R, Iswara K, et al: Drug-induced acute pancreatitis: An evidence-based review. Clin Gastroenterol Hepatol 2007; 5:648-661
138. Trivedi CD, Pitchumoni CS: Drug-induced pancreatitis: An update. J Clin Gastroenterol 2005; 39:709-716
139. Herbert MK, Roth-Goldbrunner S, Holzer P, et al: Clonidine and dexmedetomidine potently inhibit peristalsis in the Guinea pig ileum in vitro. Anesthesiology 2002; 97: 1491-1499
140. Tarling MM, Toner CC, Withington PS, et al: A model of gastric emptying using paracetamol absorption in intensive care patients. Intensive Care Med 1997; 23: 256-260
141. Talley NJ, Jones M, Nuyts G, et al: Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 2003; 98:1107-1111
142. Ness J, Hoth A, Barnett MJ, et al: Anticholinergic medications in community-dwelling older veterans: prevalence of anticholinergic symptoms, symptom burden, and adverse drug events. Am J Geriatr Pharmacother 2006; 4:42-51
143. Opie LH: Calcium channel antaǵonists. Part IV: Side effects and contraindications drug interactions and combinations. Cardiovasc Drugs Ther 1988; 2:177-189
144. Catapress-TTS (clonidine). Full prescribing information. Ridgefield, CT, Boehringer Ingelheim Pharmaceuticals, 2009
145. Disopyramide phosphate extended-release capsules, USP. Full prescribing information. St. Louis, MO, Ethex Corporation, 2000
146. Hallberg L, Ryttinger L, Solvell L: Sideeffects of oral iron therapy. A double-blind study of different iron compounds in tablet form. Acta Med Scand Suppl 1966; 459: 3-10
147. Trindade E, Menon D, Topfer LA, et al: Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis. CMAJ 1998; 159:1245-1252
148. Carafate (sucralfate) tablets. Full prescribing information. Birmingham, AL, Axcan Pharma US, 2007
149. Hallerback B, Carlsen E, Carlsson K, et al: Beta-adrenoceptor blockade in the treatment of postoperative adynamic ileus. Scand J Gastroenterol 1987; 22: 149-155
150. Cunha BA: Nosocomial diarrhea. Crit Care Clin 1998; 14:329-338
151. Condon RE, Anderson MJ: Diarrhea and colitis in clindamycin-treated surgical patients. Arch Surg 1978; 113:794-797
152. Owens FJ Sr: The clinical approach to the evaluation of diarrhea. Prim Care 1981; 8:285-307
153. Richardson G, Dobish R: Chemotherapy induced diarrhea. J Oncol Pharm Pract 2007; 13:181-198
154. Aranesp (darbopoetin alfa) for injecton. Full prescribing information. Thousand Oaks, CA, Amgen, 2009
155. Procrit (epoetin alfa) for injection. Full prescribing information. Raritan, NJ, Ortho Biotech Products, 2009
156. Jackson IM, Barnard LB, Lamberton P: Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 1986; 81:94-101
157. Robinson JD, Burtner DE: Severe diarrhea secondary to propranolol. Drug Intell Clin Pharm 1981; 15:49-50
158. Pilotto A, Franceschi M, Vitale D, et al: The prevalence of diarrhea and its association with drug use in elderly outpatients: a multicenter study. Am J Gastroenterol 2008; 103:2816-2823
159. Regan KL: Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: A literature review. J Cardiovasc Nurs 2008; 23:489-496
160. Hill DB, Henderson LM, McClain CJ: Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. JPEN J Parenter Enteral Nutr 1991; 15: 332-336
161. Benson AB III, Ajani JA, Catalano RB, et al: Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22:2918-2926
162. Dial MS: Proton pump inhibitor use and enteric infections. Am J Gastroenterol 2009; 104(Suppl 2):S10-S16